Barinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) saw a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 14,100 shares, a growth of 39.6% from the March 31st total of 10,100 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 22,000 shares, the short-interest ratio is presently 0.6 days.
Barinthus Biotherapeutics Stock Performance
Shares of NASDAQ:BRNS traded up $0.07 on Friday, hitting $2.50. The company had a trading volume of 6,864 shares, compared to its average volume of 30,951. Barinthus Biotherapeutics has a 52-week low of $1.64 and a 52-week high of $5.10. The business has a 50 day moving average of $2.69. The firm has a market capitalization of $97.30 million, a P/E ratio of -1.30 and a beta of -0.52.
Barinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report) last issued its quarterly earnings data on Wednesday, March 20th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.10. On average, research analysts predict that Barinthus Biotherapeutics will post -2.6 EPS for the current fiscal year.
Analysts Set New Price Targets
Several analysts have weighed in on BRNS shares. William Blair reissued an "outperform" rating on shares of Barinthus Biotherapeutics in a report on Monday, January 8th. HC Wainwright reissued a "buy" rating and issued a $8.00 target price on shares of Barinthus Biotherapeutics in a report on Friday, April 19th.
Read Our Latest Report on BRNS
About Barinthus Biotherapeutics
(
Get Free Report)
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Barinthus Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Barinthus Biotherapeutics wasn't on the list.
While Barinthus Biotherapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
